亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

医学 多西紫杉醇 曲妥珠单抗 帕妥珠单抗 转移性乳腺癌 肿瘤科 安慰剂 内科学 乳腺癌 化疗 癌症 病理 替代医学
作者
Sandra M. Swain,Jose M Baselga,Sung‐Bae Kim,Jungsil Ro,Vladimir Semiglazov,Mario Campone,Eva Ciruelos,Jean-­Marc Ferrero,Andreas Schneeweiß,Sarah Heeson,Emma Clark,Graham A. Ross,Mark C. Benyunes,Javier Cortés
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:372 (8): 724-734 被引量:2162
标识
DOI:10.1056/nejmoa1413513
摘要

BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
年轻班完成签到,获得积分10
4秒前
勤劳晋鹏完成签到,获得积分10
11秒前
22秒前
colin发布了新的文献求助10
28秒前
plusweng完成签到 ,获得积分10
28秒前
LHY完成签到,获得积分10
43秒前
炙热白开水完成签到,获得积分20
49秒前
单薄代珊完成签到,获得积分10
51秒前
54秒前
54秒前
54秒前
1分钟前
xccccccc发布了新的文献求助10
1分钟前
平淡的蓉完成签到,获得积分10
1分钟前
colin完成签到,获得积分10
1分钟前
传统的金鱼完成签到,获得积分10
1分钟前
英俊的铭的应助被活力的思山采纳,获得10
1分钟前
冷艳千柳完成签到,获得积分10
1分钟前
donglin完成签到,获得积分10
1分钟前
赘婿的应助被yuanzhennihao采纳,获得10
1分钟前
2分钟前
2分钟前
2分钟前
yuanzhennihao发布了新的文献求助10
2分钟前
2分钟前
调皮的钥匙完成签到,获得积分10
2分钟前
2分钟前
迅速的书雁完成签到,获得积分10
2分钟前
2分钟前
yuanzhennihao完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
852的应助被LJH采纳,获得10
2分钟前
2分钟前
2分钟前
n01W97的应助被科研通管家采纳,获得20
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834063
捐赠科研通 7782589
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206